SCHEMBL520241

SCHEMBL520241

CC(C)(C)OC(=O)N1CCN(c2cccc3cc(N)cnc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.50
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
SMARCA2 P51531 1/20 0.49
SMARCA4 P51532 1/20 0.49
PBRM1 Q86U86 1/20 0.49
PTPN11 Q06124 1/20 0.48
BACE1 P56817 2/20 0.46
PIK3CA P42336 1/20 0.46
KIT P10721 2/20 0.45
ACHE P22303 2/20 0.44
PARP1 P09874 1/20 0.44
GPR119 Q8TDV5 1/20 0.43
POLB P06746 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
MAPT P10636 2/20 0.41
CYP11B2 P19099 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520960 0.87 CKS1B (0.49) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL4800091 0.83 CKS1B (0.51) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL1048457 0.82 POLB (0.55) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL2197307 0.81 HTR2A (0.63) CKS1BSKP1SKP2SMARCA2SMARCA4
SCHEMBL4701379 0.80 TGM2 (0.47) CKS1BSKP1SKP2PIK3CAGPR119
SCHEMBL2878173 0.80 KMT2A (0.49) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL4800390 0.80 MAPT (0.45) MAP4K4CKS1BSKP1SKP2BACE1
SCHEMBL2854558 0.80 HRH1 (0.47) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL2878178 0.80 KMT2A (0.49) MAP4K4CKS1BSKP1SKP2SMARCA2
SCHEMBL4802880 0.79 MAPK1 (0.46) CKS1BSKP1SKP2ACHEGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 MAP4K4 325/4885CKS1B 464/4885SKP1 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.